Quick Takeaways: Why It Matters? ECO’s licence of Vaxinano’s late‑stage sheep toxoplasmosis vaccine gives it a low‑cost, de‑risked way to add a high‑value preventative product that directly tackles a major cause of abortion and lamb losses, with peak sales estimated a...
Quick Takeaways: Why It Matters? Medgene’s launch could be a meaningful de-risking event for cattle producers because it creates the first U.S. prescription vaccine option for a parasite with severe herd-level consequences and no approved treatment, potentially reducing losses from mortali...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
The European Medicines Agency (EMA) is continuing to accelerate innovation in animal healthcare, with its 2025 veterinary approvals reflecting strong momentum across poultry vaccines, companion animal therapeutics, livestock disease prevention, and aquaculture solutions. The latest wave of...
